Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263329 | 0.92 | PRKD3 (0.33) | MEN1KMT2AALDH1A1CYP2C9CYP2C19 | |
| Potassium Ion SCHEMBL9152245 | 0.84 | — | — | |
| SCHEMBL170998 | 0.77 | ALDH1A1 (0.39) | MEN1PKMKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL19357602 | 0.76 | PRKD3 (0.34) | MEN1PKMKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27426620 | 0.76 | CASP6 (0.38) | MEN1PKMKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL28120681 | 0.72 | MEN1 (0.39) | MEN1PKMKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9293198 | 0.69 | CASP6 (0.47) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP2C9 | |
| SCHEMBL2405485 | 0.67 | MEN1 (0.49) | MEN1PKMKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4432678 | 0.64 | — | — | |
| SCHEMBL21404284 | 0.63 | CLTC (0.40) | MEN1KMT2AALDH1A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0853680-B1 | METHOD FOR PRECIPITATING NUCLEIC ACID WITH VISIBLE CARRIER | EMD BIOSCIENCES INC (US) | 2004-03-31 | — | — | EP | claimed |
| WO-2024148174-A1 | PEPTIDE SEQUENCER | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-3500595-B1 | ANTI-PSMA ANTIBODIES, USES THEREOF AND CONJUGATES THEREOF | ABZENA UK LTD (GB) | 2024-05-01 | — | — | EP | disclosed |
| US-11865183-B2 | Conjugates and conjugating reagents comprising a linker that includes at least two (−CH2—CH2—O—) units in a ring | POLYTHERICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| EP-4282434-A2 | ANTIBODIES, USES THEREOF AND CONJUGATES THEREOF | Abzena (UK) Limited (GB) | 2023-11-29 | — | — | EP | disclosed |
| EP-3464379-B1 | ANTIBODIES, USES THEREOF AND CONJUGATES THEREOF | ABZENA UK LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| EP-3220956-B1 | CONJUGATES AND CONJUGATING REAGENTS | ABZENA UK LTD (GB) | 2023-08-09 | — | — | EP | disclosed |
| US-11485792-B2 | Antibodies, uses thereof and conjugates thereof | POLYTHERICS LIMITED | 2022-11-01 | — | — | US | disclosed |
| CN-109152845-B | Comprising at least two (-CH) s within a ring2-CH2Conjugates of linkers of-O-) units and conjugation reagents | 宝力泰锐克斯有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-109152846-B | Conjugates and conjugation reagents | 宝力泰锐克斯有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20070178601-A1 | METHOD FOR PRECIPITATING NUCLEIC ACID WITH VISIBLE CARRIER | EMD BIOSCIENCES, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070173470-A1 | Methods for delivering extracellular target into cells | NATIONAL YANG-MING UNIVERSITY (TW) | 2007-07-26 | — | — | US | disclosed |
| US-7144713-B1 | Method for precipitating nucleic acid with visible carrier | EMD BIOSCIENCES, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-0853680-B1 | METHOD FOR PRECIPITATING NUCLEIC ACID WITH VISIBLE CARRIER | EMD BIOSCIENCES INC (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1129345-A1 | PRACTICAL DEVICE FOR CONTROLLING ULTRASMALL VOLUME FLOW | ARIZONA BOARD OF REGENTS (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000028315-A1 | PRACTICAL DEVICE FOR CONTROLLING ULTRASMALL VOLUME FLOW | ARIZONA BOARD OF REGENTS (US) | 2000-05-18 | — | — | WO | disclosed |
| EP-0515379-A4 | ELECTRO-BLOTTING OF ELECTROPHORETICALLY RESOLVED FLUORESCENT-LABELED SACCHARIDES AND DETECTION OF ACTIVE STRUCTURES WITH PROTEIN PROBES | GLYCOMED INC (US) | 1994-09-14 | — | — | EP | disclosed |
| EP-0515379-A1 | ELECTRO-BLOTTING OF ELECTROPHORETICALLY RESOLVED FLUORESCENT-LABELED SACCHARIDES AND DETECTION OF ACTIVE STRUCTURES WITH PROTEIN PROBES | GLYCOMED INCORPORATED (US) | 1992-12-02 | — | — | EP | disclosed |
| US-5094731-A | ELECTRO-BLOTTING OF ELECTROPHORETICALLY RESOLVED FLUORESCENT-LABELED SACCHARIDES AND DETECTION OF ACTIVE STRUCTURES WITH PROTEIN PROBES | GLYCOMED, INC. (US) | 1992-03-10 | — | — | US | disclosed |
| WO-1991012276-A1 | ELECTRO-BLOTTING OF ELECTROPHORETICALLY RESOLVED FLUORESCENT-LABELED SACCHARIDES AND DETECTION OF ACTIVE STRUCTURES WITH PROTEIN PROBES | GLYCOMED INCORPORATED (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485792-B2 | Antibodies, uses thereof and conjugates thereof | KLK3, VSIG8, IGLV6-57 | MEN1 818/4885PKM 2121/4885KMT2A 96/4885 |
| US-11865183-B2 | Conjugates and conjugating reagents comprising a linker that includes at least two (−CH2—CH2—O—) units in a ring | BCR, CD2BP2, LANCL2 | MEN1 331/4885PKM 4261/4885KMT2A 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.